Climate Change Data

Chiesi Farmaceutici SpA SB

Climate Impact & Sustainability Data (2020, 2021, 2023)

Reporting Period: 2020

Environmental Metrics

Total Carbon Emissions:815.115 tCO2e/year
Scope 1 Emissions:43.846 tCO2e/year
Scope 2 Emissions:2.030 tCO2e/year
Scope 3 Emissions:769.239 tCO2e/year

ESG Focus Areas

  • Climate Change
  • Diversity & Inclusion
  • Shared Value
  • Patient-centricity
  • Sustainable Products
  • Supply Chain Sustainability
  • Community Engagement

Environmental Achievements

  • Achieved LEED Platinum certification for new headquarters in Parma, Italy.
  • Reduced water withdrawal by 9% compared to 2019.
  • Reduced waste production by 6% compared to 2019.
  • Increased recycling to more than 50% of total waste (+6% vs. 2019).
  • Increased shipments by sea by 20% and decreased shipments by air by 12%.
  • Committed €350 million to develop a new carbon minimal inhaler by 2025, aiming for a 90% reduction in carbon footprint.
  • Launched inhaler recycling programs in the UK and France.

Social Achievements

  • Donated over €10 million in equipment, funds, and resources to hospitals, associations, and local institutions during the COVID-19 pandemic.
  • Expanded Global Rare Diseases Unit in Boston, recruiting over 150 people.
  • Launched a strategic collaboration with Moderna for respiratory disease innovation.
  • Implemented a patient-centric strategy, including ethnographic interviews with patients and caregivers.
  • Created a Gender Equality Committee to address inequalities.
  • Ranked 10th worldwide on the FT annual Diversity Leaders ranking.
  • 53% of Chiesi’s employees are women (64% in R&D).

Governance Achievements

  • Became a Benefit Corporation in Italy and the US.
  • Obtained B Corp certification.
  • Implemented a Code of Interdependence with suppliers based on UN SDGs, PSCI, ILO, and B Corp principles.
  • Established a structured governance for shared value integration, including an Impact Committee reporting to the Board of Directors.
  • Integrated ESG issues into Enterprise Risk Management (ERM) procedures.

Climate Goals & Targets

Long-term Goals:
  • Become carbon neutral by 2035.
  • Reduce absolute scope 3 GHG emissions from the use of sold products by 90% compared to 2019 by 2035.
Medium-term Goals:
  • Reduce direct (Scope 1) and indirect (Scope 2) GHG emissions by at least 50% by 2030.
  • Transition to 100% renewable energy at all sites by 2030.
Short-term Goals:
  • Reduce GHG emissions per unit of inhaled products sold by over 80% by 2030 (Scope 3).

Environmental Challenges

  • COVID-19 pandemic impacting manufacturing, logistics, and community needs.
  • Challenges in developing drugs for rare diseases due to limitations and obstacles.
  • Industry's lack of readiness to incorporate environmental sustainability principles in product design.
Mitigation Strategies
  • Established Chiesi Emergency Management (CEM) teams to protect employees.
  • Found alternative transportation means to ensure timely delivery of medicinal products.
  • Provided psychological support and increased salaries for workers in facilities.
  • Supported patient-focused and patient-led projects to shape a better future for people living with respiratory and rare diseases.
  • Developed a Life Cycle Perspective (LCP) tool in R&D to assess environmental impacts of products.
  • Joined the B Corp Climate Collective (BCCC) and committed to the UNFCCC “Race to Zero” campaign.

Supply Chain Management

Supplier Audits: 75 new significant suppliers signed in 2020, including Code of Interdependence clause.

Responsible Procurement
  • Code of Interdependence based on UN SDGs, PSCI, ILO, and B Corp principles.

Climate-Related Risks & Opportunities

Opportunities
  • Development of energy-efficient products and processes.

Reporting Standards

Frameworks Used: GRI, B Impact Assessment, Benefit Corporation legal framework, UN SDGs

Certifications: B Corp

Sustainable Products & Innovation

  • New carbon minimal inhaler

Awards & Recognition

  • Green World Award (employee achievement)

Reporting Period: 2021

Environmental Metrics

Total Carbon Emissions:43,709 tCO2e/year
Scope 1 Emissions:172,758 tCO2e/year
Scope 2 Emissions:13,741 tCO2e/year
Renewable Energy Share:5.2%
Total Energy Consumption:1,818 GJ/year
Water Consumption:278,893 m3/year
Waste Generated:802,048 tons/year

ESG Focus Areas

  • Climate Change
  • Diversity & Inclusion
  • Patient Care
  • Community Engagement
  • Supply Chain Sustainability
  • Privacy and Data Security

Environmental Achievements

  • Launched #ActionOverWords campaign to emphasize measurable progress in sustainability.
  • Unveiled plan to become carbon neutral by 2030 (scopes 1 & 2) and 2035 (scope 3).
  • Targets approved by Science Based Target initiative (SBTi).
  • Launched Eco-Friendly Products Challenge.
  • Joined B Corp Climate Collective (BCCC) and UNFCCC's Race to Zero.
  • Progressed Carbon Minimal Inhaler project, entering clinical trials.

Social Achievements

  • Increased overall internal workforce by 3%, driven by Chiesi Global Rare Diseases and Chiesi China expansion.
  • Launched global Well-being policy with guidelines focusing on work-life harmony, volunteering, well-being education, healthcare, and welfare.
  • Rolled out diversity and inclusion awareness program.
  • Launched Global Gender Equality Challenge to achieve equal pay and opportunities by 2023.
  • #wewearstripes social media campaign raised €100,000 for EURORDIS.

Governance Achievements

  • Reviewed and updated Chiesi Code of Conduct.
  • Completed International Compliance Assurance Programme (ICAP).
  • Integrated risk assessment and strategic planning processes, including ESG risks.
  • Improved structure for integrating ESG risks into Risk Management framework.
  • Engaged in B Corp recertification process.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Become carbon neutral by 2030 (scopes 1 & 2) and 2035 (scope 3).
Short-term Goals:
  • Reduce unexplained pay gap and reach Equal Pay by 2023.

Environmental Challenges

  • Global supply chain issues and energy crisis.
  • Covid-19 pandemic's impact on healthcare systems and patient access to care.
  • Need to reduce carbon footprint from inhalers.
Mitigation Strategies
  • Adapted working models to support employees during the pandemic.
  • Developed flexible working policy and employee support programs.
  • Carbon Minimal Inhaler project to reduce emissions from inhalers.
  • Improved structure for integrating ESG risks into Risk Management framework.

Supply Chain Management

Supplier Audits: 90% of Chiesi spend covered with vendor qualification in 2021

Responsible Procurement
  • Code of Interdependence
  • Vendor qualification process
  • EcoVadis sustainability ratings

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: B Impact Assessment

Certifications: B Corp

UN Sustainable Development Goals

  • 3
  • 5
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 17

Chiesi's activities contribute to these SDGs through its business model, community engagement, and sustainability initiatives.

Sustainable Products & Innovation

  • Carbon Minimal Inhaler

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:949,619 t CO2e (Scope 3)
Scope 1 Emissions:29.906 t CO2e
Scope 2 Emissions:12.254 t CO2e (location based), 591 t CO2e (market based)
Scope 3 Emissions:949,619 t CO2e
Renewable Energy Share:99%
Total Energy Consumption:498.908 GJ
Water Consumption:299.89 ML (withdrawal), 98.75 ML (consumption)

ESG Focus Areas

  • Climate Change
  • Sustainable Development Goals (SDGs)
  • Gender Equality
  • Community Development
  • Responsible Business Practices
  • Value Chain Sustainability
  • Governance

Environmental Achievements

  • Achieved 99% renewable electricity consumption in 2023.
  • Reduced energy intensity by 28% from 2019 baseline.
  • Reduced Scope 1 CO2e emissions by 12% from 2019 baseline.
  • Reduced Scope 2 (market-based) CO2e emissions by 96% from 2019 baseline.
  • Reduced intensity of Scope 1 + 2 (market-based) CO2e emissions by 53% from 2019 baseline.
  • Introduced new packaging for a key product, replacing polystyrene with FSC-certified paper.
  • Achieved LEED Platinum certification for new headquarters and Warsaw office, LEED Gold for other buildings.
  • Obtained Ecovadis Platinum medal with a score of 78/100.

Social Achievements

  • Achieved a gender pay gap below 1% at the Group level.
  • Implemented the “Mentors for Her Growth Program”, training 14 mentors.
  • Created a Group Parenthood Policy.
  • Launched a global information platform for parents of premature neonates.
  • Successfully launched or sustained local chapters of the International Respiratory Coalition in 12 countries.
  • Conducted three carbon management workshops for over 50 suppliers.
  • Sponsored Ecovadis Academy for 104 suppliers.

Governance Achievements

  • Onboarded Shared Value & Sustainability Business Partners across all affiliates.
  • Created the SV&S Legal & Compliance role.
  • Launched an ESG preparedness program for the Group Executive Leadership Team.
  • Initiated a similar program for the Board of Directors.
  • Achieved ISO 37001:2016 certification (in 2024).

Climate Goals & Targets

Long-term Goals:
  • Reduce absolute Scope 3 GHG emissions by 90% by 2035.
  • Achieve Net Zero GHG emissions across the value chain by 2035.
Medium-term Goals:
  • Achieve 100% renewable electricity by 2025.
Short-term Goals:
  • Reduce Scope 1 and 2 GHG emissions by 90% by 2030.
  • Reduce Scope 3 GHG emissions from use of sold products by 80% per unit by 2030.
  • Complete clinical development for Carbon Minimal pMDI portfolio by 2025.

Environmental Challenges

  • Supply chain disruptions due to extreme weather events (particularly in Pakistan, China, Mexico, Spain, USA, and Italy).
  • Emerging regulations on F-gases and PFAS substances.
  • Potential introduction of carbon tax in various countries.
  • Increasing competition from products with reduced climate impact.
Mitigation Strategies
  • Developed a Climate Transition Plan.
  • Invested €350 million in the Carbon Minimal Inhaler project.
  • Implemented a comprehensive risk assessment of climate-related physical risks across 93 operational sites.
  • Strengthened requirements for EcoVadis or equivalent ESG rating tools in partner selection.
  • Actively supporting sector-wide initiatives like Energize to promote renewable energy in the supply chain.
  • Developed a Code of Interdependence to engage suppliers in sustainability.

Supply Chain Management

Supplier Audits: 118 improvement plans launched for suppliers (Ecovadis)

Responsible Procurement
  • EcoVadis assessments
  • Code of Interdependence
  • Energize program

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events
  • Water scarcity
  • Rising temperatures
Transition Risks
  • Changes in regulations related to F-gases and PFAS substances
  • Carbon pricing mechanisms
  • Changes in customer preferences
Opportunities
  • Shifting towards renewable energy sources
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: Società Benefit (Italian Law 208/2015), Non-Financial Reporting Directive (NFRD), B Impact Assessment (BIA), SDG Action Manager, GRI Standards, World Economic Forum’s ‘Measuring Stakeholder Capitalism’ Framework, Task Force on Climate-Related Financial Disclosures (TCFD)

Certifications: B Corp, LEED Platinum (Headquarters, Warsaw office), LEED Gold (other buildings), ISO 14064

UN Sustainable Development Goals

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15

Chiesi uses the SDG Action Manager to track progress towards achieving the SDGs.

Sustainable Products & Innovation

  • Carbon Minimal Inhalers

Awards & Recognition

  • Ecovadis Platinum medal